000292086 001__ 292086
000292086 005__ 20240806181039.0
000292086 0247_ $$2doi$$a10.1212/WNL.0000000000209698
000292086 0247_ $$2pmid$$apmid:39102613
000292086 0247_ $$2ISSN$$a0028-3878
000292086 0247_ $$2ISSN$$a1526-632X
000292086 037__ $$aDKFZ-2024-01590
000292086 041__ $$aEnglish
000292086 082__ $$a610
000292086 1001_ $$0P:(DE-He78)7a5d9437d9f4f1be08abac88e2018fa6$$aKaulen, Leon$$b0$$eFirst author$$udkfz
000292086 245__ $$aClinical Presentation, Management, and Outcome in Neurolymphomatosis: A Systematic Review.
000292086 260__ $$a[Erscheinungsort nicht ermittelbar]$$bOvid$$c2024
000292086 3367_ $$2DRIVER$$aarticle
000292086 3367_ $$2DataCite$$aOutput Types/Journal article
000292086 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1722951098_24529
000292086 3367_ $$2BibTeX$$aARTICLE
000292086 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000292086 3367_ $$00$$2EndNote$$aJournal Article
000292086 500__ $$a#EA:B320#LA:B320#
000292086 520__ $$aNeurolymphomatosis (NL) refers to lymphomatous infiltration of the peripheral nervous system (PNS). NL diagnosis and treatment are challenging given the broad differential diagnosis of peripheral neuropathy, the lack of larger cohorts, and the subsequent unavailability of prognostic factors or consensus therapy. This study aimed to define characteristics and prognostic factors of NL.A systematic review of the literature (2004-2023) was performed using PubMed and Scopus databases and reported following PRISMA guidelines. Studies reporting individual patient data on cases with definitive NL diagnosis were included. Clinical, radiologic, pathologic, and outcome information were extracted. Univariable and multivariable survival analyses were performed using log-rank tests and Cox proportional hazard models.A total of 459 NL cases from 264 studies were accumulated. NL was the first manifestation of malignancy (primary NL) in 197 patients. PNS relapse of known non-Hodgkin lymphoma (secondary NL) occurred in 262 cases after a median 12 months. NL predominantly presented with rapidly deteriorating, asymmetric painful polyneuropathy. Infiltrated structures included peripheral nerves (56%), nerve roots (52%), plexus (33%), and cranial nerves (32%). Diagnosis was established at a median of 3 months after symptom onset with substantial delays in primary NL. It mainly relied on PNS biopsy or FDG-PET, which carried high diagnostic yields (>90%). Postmortem diagnoses were rare (3%). Most cases were classified as B-cell (90%) lymphomas. Tumor-directed therapy was administered in 96% of patients and typically consisted of methotrexate or rituximab-based polychemotherapy. The median overall survival was 18 months. Primary NL without concurrent systemic disease outside the nervous system (hazard ratio [HR]: 0.44; 95% CI 0.25-0.78; p = 0.005), performance status (ECOG <2, HR: 0.30; 95% CI 0.18-0.52; p < 0.0001), and rituximab-based treatment (HR: 0.46; 95% CI 0.28-0.73; p = 0.001) were identified as favorable prognostic markers on multivariable analysis when adjusting for clinical and sociodemographic parameters.Advances in neuroimaging modalities, particularly FDG-PET, facilitate NL diagnosis and offer a high diagnostic yield. Yet, diagnostic delays in primary NL remain common. Rituximab-based therapy improves NL outcome. Findings may assist clinicians in early recognition, prognostic stratification, and treatment of NL.
000292086 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000292086 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000292086 650_2 $$2MeSH$$aHumans
000292086 650_2 $$2MeSH$$aNeurolymphomatosis: therapy
000292086 650_2 $$2MeSH$$aNeurolymphomatosis: diagnostic imaging
000292086 650_2 $$2MeSH$$aDisease Management
000292086 650_2 $$2MeSH$$aPrognosis
000292086 7001_ $$0P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aHielscher, Thomas$$b1$$udkfz
000292086 7001_ $$00009-0003-1727-8906$$aDoubrovinskaia, Sofia$$b2
000292086 7001_ $$0P:(DE-He78)e50ff195896914d35f54ed1bf913e270$$aHoffmann, Dirk Carsten Frieder$$b3$$udkfz
000292086 7001_ $$0P:(DE-He78)5c2c9cbe6ce72553684d82d94aebdadd$$aKessler, Tobias$$b4$$udkfz
000292086 7001_ $$aTraub, Benjamin-Leon$$b5
000292086 7001_ $$aBaehring, Joachim M$$b6
000292086 7001_ $$0P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee$$aWick, Wolfgang$$b7$$eLast author$$udkfz
000292086 773__ $$0PERI:(DE-600)1491874-2$$a10.1212/WNL.0000000000209698$$gVol. 103, no. 4, p. e209698$$n4$$pe209698$$tNeurology$$v103$$x0028-3878$$y2024
000292086 909CO $$ooai:inrepo02.dkfz.de:292086$$pVDB
000292086 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)7a5d9437d9f4f1be08abac88e2018fa6$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000292086 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000292086 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e50ff195896914d35f54ed1bf913e270$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000292086 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5c2c9cbe6ce72553684d82d94aebdadd$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000292086 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000292086 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000292086 9141_ $$y2024
000292086 915__ $$0StatID:(DE-HGF)0410$$2StatID$$aAllianz-Lizenz$$d2023-10-21$$wger
000292086 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEUROLOGY : 2022$$d2023-10-21
000292086 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-21
000292086 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-21
000292086 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-21
000292086 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-21
000292086 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-21
000292086 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-21
000292086 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-21
000292086 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-21
000292086 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-21
000292086 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-21
000292086 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-21
000292086 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bNEUROLOGY : 2022$$d2023-10-21
000292086 9202_ $$0I:(DE-He78)B320-20160331$$kB320$$lKKE Neuroonkologie$$x0
000292086 9201_ $$0I:(DE-He78)B320-20160331$$kB320$$lKKE Neuroonkologie$$x0
000292086 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x1
000292086 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000292086 9200_ $$0I:(DE-He78)B320-20160331$$kB320$$lKKE Neuroonkologie$$x0
000292086 980__ $$ajournal
000292086 980__ $$aVDB
000292086 980__ $$aI:(DE-He78)B320-20160331
000292086 980__ $$aI:(DE-He78)C060-20160331
000292086 980__ $$aI:(DE-He78)HD01-20160331
000292086 980__ $$aUNRESTRICTED